The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Abstract
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–206 of 206
Jia, J., Zhang, D., Ludwig, J. M., & Kim, H. S. (2017) · Clinical Radiology · doi:10.1016/j.crad.2017.07.024 · Cited by 31
Lu, L., Zeng, J., Wen, Z., Tang, C., & Xu, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012244.pub2 · Cited by 30
Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999–2009
Melkonian, S. C., Jim, M. A., Reilley, B. A., Erdrich, J., Berkowitz, Z., Wiggins, C. L., Haverkamp, D. S., & White, M. C. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1059-3 · Cited by 28
Prospective evaluation of the management of hepatocellular carcinoma in the elderly
Ozenne, V., Bouattour, M., Goutté, N., Vullierme, M., Ripault, M., Castelnau, C., Valla, D. C., Degos, F., & Farges, O. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.06.019 · Cited by 25
Chapelle, T., de Beeck, B. O., Roeyen, G., Bracke, B., Hartman, V., Greef, K. E. D., Huyghe, I., van der Zijden, T., Morrison, S. G., Francque, S., et al. (2016) · HPB · doi:10.1016/j.hpb.2016.11.005 · Cited by 24
Tong, M. J., Rosinski, A. A., Huynh, C. T., Raman, S. S., & Lu, D. (2017) · Hepatology Communications · doi:10.1002/hep4.1047 · Cited by 23
Self-citation
Cited by
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Self-citationSingal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationPeng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., Cheng, Y., Huang, Z., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00392 · Cited by 460
Roa, J. C., García, P., Kapoor, V. K., Maithel, S. K., Javle, M., & Koshiol, J. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00398-y · Cited by 401
Metadata
- Authors
- Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., Chahal, P., Chang, D. T., Cloyd, J., Covey, A. M., Glazer, E. S., Goyal, L., Hawkins, W. G., Iyer, R., Jacob, R., Kelley, R. K., Kim, R., Levine, M., Palta, M., Park, J. O., Raman, S., Reddy, S., Sahai, V., Schefter, T., Singh, G., Stein, S., Vauthey, J.-N., Venook, A. P., Yopp, A., McMillian, N. R., Hochstetler, C., & Darlow, S. D.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-05
- Volume
- 19
- Issue
- 5
- Pages
- 541-565
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3165133969
- Cited by
- 1,003
- References
- 206
- FWCI
- 86.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.